이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

호산구성 질환이 있는 소아에서 벤랄리주맙을 조사하기 위한 시험 (CLIPS)

2026년 10월 27일 업데이트: AstraZeneca

3상, 호산구성 질환이 있는 소아에서 벤랄리주맙의 안전성, 약동학 및 효능을 평가하기 위한 공개 라벨 시험(CLIPS)

The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.

연구 개요

상세 설명

This study is open-label, multicentre, basket study to evaluate the safety, PK, pharmacodynamic (PD), efficacy, and immunogenicity of repeat dosing of benralizumab subcutaneous (SC) every 4 weeks (Q4W) in male and female children with rare eosinophilic diseases.

Paediatric participants with eosinophilic granulomatosis with polyangiitis (EGPA) will be enrolled in the first cohort.

Paediatric participants with hypereosinophilic syndrome (HES) will be enrolled in the second cohort. Additional cohorts in other eosinophilic diseases may be added in future protocol amendments.

The study consists of 3 periods:

  1. Screening period: 1 to 4 weeks
  2. Open-label treatment period: 52 weeks
  3. Open-label extension period: at least 52 weeks (plus safety follow-up [SFU] weeks after last investigational product [IP] administration)

All eligible participants will receive benralizumab SC Q4W during the 52-week open-label treatment period.

All participants who complete the 52-week open-label treatment period on IP will be offered the opportunity to continue into an extension period. The extension period is intended to allow each participant at least an additional one year of treatment with benralizumab.

연구 유형

중재적

등록 (추정된)

14

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Rotterdam, 네덜란드, 3015 GD
        • 모병
        • Research Site
      • Guadalajara, 멕시코, 44620
        • 모병
        • Research Site
    • Colorado
      • Aurora, Colorado, 미국, 80045
        • 모병
        • Research Site
    • Ohio
      • Cincinnati, Ohio, 미국, 45229
        • 모병
        • Research Site
      • Highland Hills, Ohio, 미국, 44106-2624
        • 모병
        • Research Site
      • São Paulo, 브라질, 01232-010
        • 모병
        • Research Site
      • Petah Tikva, 이스라엘, 49202
        • 모병
        • Research Site
      • Ahmedabad, 인도, 380052
        • 모병
        • Research Site
    • Ontario
      • Toronto, Ontario, 캐나다, M5G1X8
        • 모병
        • Research Site
      • Altındağ, 터키 (Türkiye), 06230
        • 모병
        • Research Site
      • Istanbul, 터키 (Türkiye), 34093
        • 모병
        • Research Site
      • Kielce, 폴란드, 25-734
        • 모병
        • Research Site
      • Warsaw, 폴란드, 04-730
        • 아직 모집하지 않음
        • Research Site
      • Lille, 프랑스, 59037
        • 모병
        • Research Site
      • Montpellier, 프랑스, 34295
        • 정지된
        • Research Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

6년 (어린이)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

All Cohorts:

  • Male or female participants must be aged 6 to < 18 years of age at the time of signing the assent form and their caregiver signing the informed consent form.
  • Body weight greater than (>=) 15 kilograms (kg).

EGPA Cohort:

  • Therapy with corticosteroids: The prescribed dose of oral corticosteroids (OCS) (greater than [>] 0.1 milligrams per kilogram per day (mg/kg/day), max dose of 50 milligrams per day (mg/day) must be stable (that is, no adjustment of the dose) for at least 4 weeks prior to baseline (Visit 2).
  • Immunosuppressive therapy: If receiving immunosuppressive therapy, the dosage must be stable for at least 4 weeks prior to baseline (Visit 2).

HES Cohort:

  • Documented HES diagnosis, defined as history of persistent eosinophilia >1500 cells/µL without secondary cause on 2 examinations ≥1 month apart and evidence of eosinophil-mediated organ involvement.
  • Symptomatic active HES, or history of a prior flare, or considered eligible based on disease severity per investigator judgement.
  • AEC ≥1000 cells/µL at screening (Visit 1).
  • Documented negative testing for Fip1-like 1 gene fused with the platelet-derived growth factor receptor alpha gene (FIP1L1-PDGFR) fusion tyrosine kinase gene translocation.

Exclusion Criteria:

All Cohorts:

  • Any current malignancy or history of malignancy.
  • History of anaphylaxis to any biologic therapy or vaccine.
  • Known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological, respiratory, or any other system abnormalities.
  • Previous receipt of benralizumab in an interventional clinical study.

EGPA Cohort:

  • Diagnosed with granulomatosis with polyangiitis (previously known as Wegener'granulomatosis) or microscopic polyangiitis.
  • EGPA relapse: any deterioration in EGPA and/or organ-threatening EGPA that per Investigator judgement renders participants unstable in their EGPA within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2).
  • Life-threatening EGPA: imminently life-threatening EGPA disease within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2), as per Investigator judgement.

HES Cohort:

  • Life-threatening HES or HES complications, as judged by the investigator.
  • Hypereosinophilia of unknown significance (HE-US).
  • Diagnosis of systemic mastocytosis.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: EGPA/HES Cohort: Benralizumab

Participants with greater than or equal to (>=) 35 kg weight will receive benralizumab dose-1 and participants with less than (<) 35 kg weight will receive benralizumab dose-2 as SC injection Q4W during the 52-week treatment period. All participants who complete the 52-week treatment period will be offered the opportunity to continue into an extension period.

Benralizumab will be administered as SC injection on Q4W.

다른 이름들:
  • 파센라

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Number of Participants with Adverse Events (AEs)
기간: From screening (Week -4 to -1) until Week 52

The safety and tolerability of benralizumab will be evaluated.

From screening (Week -4 to -1) until Week 52
Serum Concentrations of Benralizumab
기간: Weeks 0, 12, 24, 25, 36, and 52

The PK of benralizumab will be evaluated.

Weeks 0, 12, 24, 25, 36, and 52

2차 결과 측정

결과 측정
측정값 설명
기간
EGPA Cohort: Percentage of Participants with Remission at Week 24
기간: At Week 24

Remission defined as Paediatric Vasculitis Activity Score (PVAS) = 0 and oral corticosteroid (OCS) intake less than or equal to (<=) 0.1 mg/kg/day.

At Week 24
Number of Participants with Positive Antidrug Antibody (ADA)
기간: Weeks 0, 12, 24, 36, 48, and 52

The immunogenicity of benralizumab will be evaluated.

Weeks 0, 12, 24, 36, 48, and 52
Change From Baseline in Peripheral Blood Eosinophil Count
기간: From Baseline to Weeks 0, 12, 24, 36, 52

The PD effect of benralizumab on peripheral blood eosinophil count will be evaluated.

From Baseline to Weeks 0, 12, 24, 36, 52
EGPA Cohort: Time to First EGPA Relapse
기간: Up to 52 weeks

The efficacy of benralizumab on time to first relapse will be assessed. EGPA relapse will be defined as worsening or persistence of active disease since the last visit characterized by: a) Active vasculitis (PVAS > 0); OR b) Worsening of asthma symptoms (based on Asthma Control Questionnaire - Interviewer Administered [ACQ-IA]); OR c) Active nasal and/or sinus disease with worsening in at least one sino-nasal symptom question warranting any of the following: 1) Increase OCS; OR 2) Increase/addition of immunosuppressive medication; OR 3) Hospitalisation related to EGPA worsening.

Up to 52 weeks
HES Cohort: Time to first HES worsening/flare
기간: Up to 52 weeks

The effect of benralizumab on HES worsening/flares will be evaluated.

Up to 52 weeks
HES Cohort: Percentage of participants who experience a HES worsening/flare
기간: Up to 52 weeks

The effect of benralizumab on HES worsening/flares will be evaluated.

Up to 52 weeks
HES Cohort: Number of HES worsening/flares (annualised rate/year)
기간: Up to 52 weeks

The effect of benralizumab on HES worsening/flares will be evaluated. The annualised HES worsening/flare rate will be calculated as follows:

The total number of flares *365.25 / total duration of follow-up in the treatment period (days).

Up to 52 weeks
HES Cohort: Percentage of Participants requiring an increase in corticosteroid dose
기간: Up to 52 weeks

The effect of benralizumab on corticosteroid use will be evaluated.

Up to 52 weeks
HES Cohort: Time to first haematologic relapse
기간: Up to 52 weeks

The time to first haematologic relapse will be defined as the time from first dose of IP to the first post baseline visit with Absolute eosinophil count [AEC] ≥ 1000 cells/uL.

Up to 52 weeks
HES Cohort: Percentage of Participants with haematologic relapse
기간: Up to 52 weeks

The effect of benralizumab on haematologic measures of disease activity will be evaluated.

Up to 52 weeks
HES Cohort: Percentage of Participants who have AEC < 500 cells/μL for 24 weeks
기간: Up to 52 weeks

The effect of benralizumab on haematologic measures of disease activity will be evaluated.

Up to 52 weeks
HES Cohort: Patient Global Impression of Change (PGI-C) Score
기간: Weeks 12, 24, 36 and 48

The effect of benralizumab on participant/caregiver reported measures of disease severity and health status will be assessed. The PGI-C instrument captures the participant's overall evaluation of response to treatment, and rated on a 7-point PGI-C scale ranging from 1 ('much better') to 7 ('much worse').

Weeks 12, 24, 36 and 48

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 4월 17일

기본 완료 (추정된)

2028년 2월 20일

연구 완료 (추정된)

2029년 5월 14일

연구 등록 날짜

최초 제출

2024년 7월 17일

QC 기준을 충족하는 최초 제출

2024년 7월 17일

처음 게시됨 (실제)

2024년 7월 22일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 28일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 27일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • D3255C00004
  • 2023-508533-14-00 (기타 식별자: EU CT)
  • EMEA-001214-PIP09-21-M02(EGPA) (기타 식별자: Paediatric Investigational Plan Number)
  • EMEA-001214-PIP04-19-M02 (HES) (기타 식별자: Paediatric Investigational Plan Number)
  • 2023 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via there quest portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD 공유 기간

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 공유 액세스 기준

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD 공유 지원 정보 유형

  • 연구_프로토콜

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다